HUTCHMED (00013) announced its full-year 2025 financial results. Total revenue was $549 million, a decrease of 12.96% year-on-year. Profit attributable to shareholders was $457 million, representing a significant increase of 1111.03% compared to the previous year. Basic earnings per share were $0.53.
Dr. Dan Eldar, Non-Executive Chairman of HUTCHMED, commented on the company's strategic direction. He stated that the team's scientific expertise in innovative drug research and development, combined with the support of advanced artificial intelligence tools, positions HUTCHMED at the forefront of exploring novel therapeutic mechanisms. Leveraging this leading position, the company is actively pursuing new technologies, products, and targets to enrich its product portfolio, supported by its robust financial reserves.
The business development team has received interest from multiple multinational pharmaceutical companies interested in collaborating to advance the development and commercialization of innovative drug candidates with potential for global market leadership. These potential partnerships are expected to further validate the scientific value and commercial potential of HUTCHMED's innovation platform. Such collaborations would allow HUTCHMED to utilize partners' global development and marketing expertise to accelerate the worldwide introduction of innovative medicines addressing significant unmet medical needs.
The success of FRUZAQLA® has validated this strategy, which is now being extended to the company's ATTC technology, with initial results anticipated within the year. Dr. Eldar described the company as being at a critical inflection point. A repositioning of the commercial team to better address current market challenges and drive sales growth in China has already shown significant results by the second quarter of 2025.
For late-stage pipeline projects, encouraging clinical results from Phase III studies have supported the submission of new drug applications. The company has also accumulated substantial experience in securing approvals from major regulatory agencies. Furthermore, the macromolecular technology platform has successfully transitioned from the drug discovery phase to clinical development, with two candidate drugs now entering clinical trials.
HUTCHMED believes this period represents a significant development opportunity, enabling it to deepen collaborations with leading global industry players, increase investment in research and development, and accelerate the realization of the platform's broad therapeutic potential.